


Application No. (if known): 10/009,508

Attorney Docket No.: 04280/000M988-US0

113



Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. _____ in an envelope addressed to:

EV 306627349 US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

#10/009/508

on 9-12-03
Date

G Karaszi
G KARASZI


Signature

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Supplemental IDS (3 pg)
Form PTO SB-08 (1 pg)
3 References

EXPRESS MAIL CERTIFICATE



Date _____ Label No. _____
I hereby certify that, on the date indicated above, this paper
or fee was deposited with the U.S. Postal Service & that it
was addressed for delivery to the Commissioner for Patents,
PO Box 1450, Alexandria, VA 22313-1450 by "Express Mail
Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print)

Signature

Customer No.: 07278

Docket No.: 04280/000M988-US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Sai L. SU

Serial No.: 10/009,508

Confirmation No.: 5007

Filed: November 6, 2001

For: METHODS FOR THE DIAGNOSIS AND TREATMENT OF METASTATIC
PROSTATE TUMORS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a
copy of Form PTO SB-08 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO SB-08) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO SB-08 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed before a first action on the merits has been mailed.

The present Supplemental Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for relevance every document cited on the attached form even if not


initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 04-0100 for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: September 12, 2003


MARIE GILFILLAN
fn Paul F. Fehlner, Ph.D. 44085
Registration No. 35,135
Attorney for Applicant(s)

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700

SEP 12 2003

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/009,508
		Filing Date	November 6, 2001
		First Named Inventor	Sai L. Su
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	04280/0M988US0
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,776,755-B1	07-07-1998	Alitalo et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO-WO 95/33772-A1	12-14-1995	Alitalo et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Karamysheva, A.F. et al.: Expression of the FLT4/VEGFR3 receptor tyrosine kinase encoding gene in hepatic tumors, <i>International Journal of Oncology</i> , 25 April 1996, Vol. 8, No. 5, pages 921-924.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

{M:428 010m98	Date Considered
------------------	--------------------